Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
2.9 EUR
404.07 M EUR
2.00 B EUR
70.10 M
About Insulet Corporation
Sector
Industry
CEO
Ashley A. McEvoy
Website
Headquarters
Acton
Founded
2000
ISIN
US45784P1012
FIGI
BBG000RL1635
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Insulet Corporation stocks are traded under the ticker GOV.
We've gathered analysts' opinions on Insulet Corporation future price: according to them, GOV price has a max estimate of 352.79 EUR and a min estimate of 255.03 EUR. Watch GOV chart and read a more detailed Insulet Corporation stock forecast: see what analysts think of Insulet Corporation and suggest that you do with its stocks.
Yes, you can track Insulet Corporation financials in yearly and quarterly reports right on TradingView.
Insulet Corporation is going to release the next earnings report on Oct 30, 2025. Keep track of upcoming events with our Earnings Calendar.
GOV earnings for the last quarter are 0.99 EUR per share, whereas the estimation was 0.78 EUR resulting in a 27.20% surprise. The estimated earnings for the next quarter are 0.98 EUR per share. See more details about Insulet Corporation earnings.
Insulet Corporation revenue for the last quarter amounts to 551.02 M EUR, despite the estimated figure of 521.40 M EUR. In the next quarter, revenue is expected to reach 576.98 M EUR.
GOV net income for the last quarter is 19.10 M EUR, while the quarter before that showed 32.72 M EUR of net income which accounts for −41.63% change. Track more Insulet Corporation financial stats to get the full picture.
No, GOV doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 25, 2025, the company has 3.9 K employees. See our rating of the largest employees — is Insulet Corporation on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Insulet Corporation EBITDA is 432.35 M EUR, and current EBITDA margin is 18.81%. See more stats in Insulet Corporation financial statements.
Like other stocks, GOV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Insulet Corporation stock right from TradingView charts — choose your broker and connect to your account.